{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:46:31Z","timestamp":1789652791153,"version":"4.0.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001229","name":"Australia and New Zealand Banking Group Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clml.2021.01.016","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T07:21:04Z","timestamp":1611991264000},"page":"e510-e520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-2813","authenticated-orcid":false,"given":"Krystal","family":"Bergin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Blacklock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.01.016_bib1","series-title":"Cancer in Australia: An Overview in 2014","year":"2014"},{"key":"10.1016\/j.clml.2021.01.016_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.01.016_bib3","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3109\/10428194.2016.1170828","article-title":"Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity","volume":"57","author":"Costa","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.016_bib4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.01.016_bib5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.016_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/asheducation.V2011.1.184.3718203","article-title":"New insights into therapeutic targets in myeloma","volume":"2011","author":"Anderson","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.01.016_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.016_bib10","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A\u00a0novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in\u00a0vitro and in\u00a0vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2021.01.016_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11899-017-0397-7","article-title":"Novel immunotherapies for multiple myeloma","volume":"12","author":"D\u2019Agostino","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.01.016_bib13","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.01.016_bib15","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib16","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.016_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/imj.12688","article-title":"Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group","volume":"45","author":"Quach","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2021.01.016_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/imj.12640","article-title":"Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group","volume":"45","author":"Quach","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2021.01.016_bib21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clml.2016.12.002","article-title":"Myeloma in the real world: what is really happening?","volume":"17","author":"Bergin","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.01.016_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/EDBK_238551","article-title":"Many shades of disparities in myeloma care","volume":"39","author":"Ganguly","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2021.01.016_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12874-016-0250-z","article-title":"Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry","volume":"16","author":"Bergin","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2021.01.016_bib25","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.01.016_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12185-011-0971-z","article-title":"Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients","volume":"95","author":"Kaya","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.01.016_bib29","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.3892\/ol.2016.5375","article-title":"Diagnostic and therapeutic approaches to multiple myeloma patients: \u201creal-world\u201d data from representative multicentre treatment surveys in Germany between 2008 and 2011","volume":"12","author":"Moehler","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2021.01.016_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bjh.14341","article-title":"Is the Revised International Staging System for myeloma valid in a real world population?","volume":"180","author":"Walker","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.016_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2021.01.016_bib32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jech.2003.008466","article-title":"Bias","volume":"58","author":"Delgado-Rodr\u00edguez","year":"2004","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.clml.2021.01.016_bib34","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.016_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.01.016_bib36","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.01.016_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.01.016_bib38","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.016_bib39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/14728222.12.11.1377","article-title":"Novel targets for myeloma bone disease","volume":"12","author":"Roodman","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clml.2021.01.016_bib40","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1046\/j.1365-2141.1998.01082.x","article-title":"Bone disease in multiple myeloma","volume":"103","author":"Croucher","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.016_bib41","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.01.016_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A\u00a0randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.016_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.01.016_bib44","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.01.016_bib45","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.016_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.beha.2007.09.006","article-title":"Role of autologous stem-cell transplantation in multiple myeloma","volume":"20","author":"Attal","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.01.016_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2021.01.016_bib48","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2021.01.016_bib49","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.01.016_bib50","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/10428194.2013.763396","article-title":"A\u00a0population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma","volume":"54","author":"Nivison-Smith","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.016_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","article-title":"Treatment evolution and improved survival in multiple myeloma in Taiwan","volume":"99","author":"Tang","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.01.016_bib52","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.12659\/MSM.907588","article-title":"Real-world clinical outcomes in elderly chinese patients with multiple myeloma: a single-center experience","volume":"24","author":"Qian","year":"2018","journal-title":"Med Sci Monitor"},{"key":"10.1016\/j.clml.2021.01.016_bib53","doi-asserted-by":"crossref","first-page":"e0208507","DOI":"10.1371\/journal.pone.0208507","article-title":"Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland, 2009-2013","volume":"13","author":"Remes","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.01.016_bib54","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)","volume":"2","author":"Verelst","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2021.01.016_bib55","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.clml.2018.04.003","article-title":"Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies","volume":"18","author":"Hajek","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.01.016_bib56","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.01.016_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:36Z","timestamp":1761870936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2152265021000343"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}